# A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis

> **NCT03145948** · PHASE1 · TERMINATED · sponsor: **AbbVie** · enrollment: 12 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** ABBV-553
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03145948
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-05-09
- **Primary completion:** 2017-08-16
- **Final completion:** 2017-08-16
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Safety reason
- **Last updated:** 2017-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03145948

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03145948, "A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03145948. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*